Biologic and Systemic Agents in Dermatology

1. Front Matter

   Pages i-xvii

   PDF

2. History of Therapies in Dermatology: Past to Present

   • Abby S. Van Voorhees, Jeffrey M. Weinberg

   Pages 1-6

3. Outcome Measures in Psoriasis and Atopic Eczema

   • Kristina Callis Duffin

   Pages 7-25

4. Interpreting Clinical Trial Data

   • Mina Amin, Daniel J. No, Kavita Darji, Jashin J. Wu

   Pages 27-36

5. Compliance and Persistency

   • Emily Boes, Jaclyn Smith, Steven R. Feldman

   Pages 37-49

6. Quality of Life in the Dermatology Practice

   • Jennifer Cather, J. Christian Cather, Melodie Young

   Pages 51-55

7. Medical Legal Issues with Biologic Agents in the Treatment of Psoriasis

   • David J. Goldberg, Allan Gibofsky

   Pages 57-60

8. Patient and Physician Perspectives on Traditional Systemic and Biologic Therapies for Psoriasis

   • Margaretta Midura, Amit Garg

   Pages 61-64

9. Outcomes of Comorbidities with Biologic and Systemic Agents

   • Megan H. Noe, Joel M. Gelfand

   Pages 65-71

10. Pharmacovigilance

    • Robert E. Kalb

    Pages 73-82

11. Pharmacoeconomics of Systemic and Biologic Therapy in Dermatology

    • Martina L. Porter, Alexa B. Kimball

    Pages 83-91

12. Immunogenicity of Biologic Agents in Psoriasis

    • Alexandra G. Florek, Kennethk B. Gordon

    Pages 93-99

13. Manufacturing of Biologics

    • Jared J. Nathan, Monica Ramchandani, Primal Kaur

    Pages 101-110

14. Tumor Necrosis Factor Inhibition

    • K. A. Papp, Mathew N. Nicholas

    Pages 111-121

15. Dual Inhibition of IL-12/IL-23 and Selective Inhibition of IL-23 in Psoriasis

    • Andrew Blauvelt

    Pages 123-131

16. Interleukin-17 Inhibition for the Treatment of Inflammatory Skin Disease

    • Jason E. Hawkes, Jose A. Gonzalez, James G. Krueger

    Pages 133-144

17. Systemic Therapies in Psoriasis

    • Gregory Peterson, Annika Silfast-Kaiser, Alan Menter

    Pages 145-158

18. Nail, Scalp, and Palmoplantar Psoriasis

    • Jeffrey J. Crowley

    Pages 159-174

19. Current and Emerging Treatments for Psoriatic Arthritis

    • Philip J. Mease

    Pages 175-185

20. Janus Kinase Inhibitors

    • Andrew Kim, Bruce Strober

    Pages 187-198

Written by leading experts in the field and designed for dermatologists and residents, this book includes evidence-based medicine that underscores the clinical data, as well as practical tips on how to use both biologic and systemic agents in the field of dermatology. In the past decade, there have been several groundbreaking advances in medical dermatology. Novel biologic and systemic agents have been developed to treat inflammatory disorders, including psoriasis and atopic dermatitis, as well as skin malignancies such as melanoma.

Biologic and Systemic Agents in Dermatology encompasses these developments by describing the mechanism of action of these various agents and the clinical efficacy and safety to treating these respective disorders. The utilization of biologic and systemic agents in other dermatologic conditions, pharmacoeconomics, pharmacovigilance, and clinical trials outcomes are discussed as well as topics including tumor necrosis, conventional systemic agents for psoriatic disease, and oral agents for atopic dermatitis.

• systemic dermatology
• biologic agents of dermatology
• psoriasis
• dermatology
• atopic dermatitis
• skin malignancies

• Division of Dermatology, David Geffen School of Medicine a UCLA, Los Angeles, USA

  Paul S. Yamauchi

Paul S. Yamauchi, M.D., Ph.D. is Clinical Assistant Professor of Dermatology, David Geffen School of Medicine at UCLA and Harbor-UCLA Medical Center and isdermatologist in private practice at the Dermatology Institute and Skin Care Center in Santa Monica, California. Dr. Yamauchi is a fellow with the American Academy of Dermatology and the American Society of Dermatology Surgery and is also a member of the Los Angeles Metropolitan Dermatologic Society and California Society of Dermatology and Dermatologic Surgery.  He is the editor-in-chief of Dermatology Reports and is the author and co-author of more than 70 publications, including several books.

 
Dr. Yamauchi conducts numerous clinical research trials at the Clinical Science Institute in Santa Monica and serves as a principle investigator in several studies, including new therapies for psoriasis, skin cancer, eczema and acne, and has been a consultant for the development of new innovative therapies in dermatology.
 
He is recognized as a key expert leader on psoriasis and has served on the Medical Board for the National Psoriasis Foundation and the Scientific Advisory Committee for the National Eczema Association. He has extensive experience using the new biologics, oral drugs, and topical medications in the treatment of psoriasis, and has been invited as a speaker at international, national, regional, and local venues to talk about new advances in the treatment of psoriasis and atopic dermatitis. In addition, he is a  strong advocate in establishing patient support groups for psoriasis, and has published extensively in new advances in the treatment of psoriasis. Dr. Yamauchi has also spoken on other dermatologic conditions at national and local meetings and has published many peer-reviewed articles including acne, eczema, skin manifestations associated with rheumotologic conditions, and hyperhidrosis.
 
He  has given several television media interviews locally in Los Angeles as well as nationally on ESPN, national news, Inside Edition, and internet webcasts. In addition, he has been quoted several times in the Los Angeles Times, Los Angeles Daily News, Dermatology Times, Skin and Allergy News, and several magazines. He has been the recipient of many awards including Marquis Who’s Who in Medicine and Healthcare, Super Doctors in Southern California, and America’s Top Physicians List among others.

Policies and ethics